Pixium Vision's share price soared by over 60% on the Paris Bourse on Tuesday, following the presentation of the 48-month results of its trial for age-related macular degeneration (AMD).

According to the bionic vision systems specialist, this study confirmed the 36-month results, i.e. 'well-tolerated' use of its subretinal prosthesis, with no reduction in natural peripheral vision.

At the end of four years, the average gain in treated patients was 32 letters, which should be considered 'clinically significant' for patients with geographic atrophy caused by AMD, according to the company.

This initial trial aimed to assess the efficacy and safety of its Prima photovoltaic retinal stimulation microchip 48 months post-implantation in patients with severe central visual field degradation due to dry age-related macular degeneration (AMD).

Pixium now expects to publish the full results of its European pivotal 'PRIMAvera' study, having enrolled 38 patients, early in the second quarter of 2024.

At 11:15 a.m., the share was reserved for the upside after posting gains of up to 63%, making it by far the biggest gainer on the Paris market.

As a reminder, the company is currently undergoing a receivership procedure and is actively seeking buyers, with a November 20 deadline for the submission of offers.

Copyright (c) 2023 CercleFinance.com. All rights reserved.